CORT

A month has gone by since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 1.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Corcept reported second-quarter 2026 earnings of 36 cents per share, outperforming the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company reported earnings of 29 cents. Second-quarter revenues rose nearly 32% year over year to $256.1 million and surpassed the Zacks Consensus Estimate of $216 million. Growth was driven by higher Korlym sales and contribution from the newly launched product, Lifyorli (relacorilant). Corcept’s top line consisted of product sales from Cushing’s syndrome drug Korlym and newly launched ovarian cancer drug Lifyorli. In the second quarter of 2026, product revenues from Korlym were $208.6 million, up 7.3% year over year. However, the metric missed our model estimate of $212.2 million. Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial sales. Second-quarter operating expenses increased 28.1% year over year to $214.8 million. The rise reflected spending related to the Lifyorli launch and continued investment in the company’s Cushing’s syndrome business. Selling, general and administrative expenses surged 51.1% to $156.9 million. Research and development expenses declined 10.9% to $53.9 million. Corcept ended the June quarter with cash and investments of $544.6 million, up from $515.4 million as of March 31, 2026. Corcept raised its 2026 revenue guidance to $1.1-$1.2 billion from the previous $950 million to $1.05 billion. Management said that the revised outlook reflects strength across the endocrinology and oncology businesses. In the past month, investors have witnessed a upward trend in estimates revision. The consensus estimate has shifted 86.02% due to these changes. Currently, Corcept has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Corcept has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Corcept belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Summit Therapeutics PLC (SMMT), has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Summit Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.28 for the same period compares with -$0.76 a year ago. For the current quarter, Summit Therapeutics is expected to post a loss of $0.28 per share, indicating a change of +9.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. Summit Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Summit Therapeutics PLC (SMMT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its peers. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing. The 8 branded pharmaceuticals stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 6.6%. Thankfully, share prices of the companies have been resilient as they are up 9.3% on average since the latest earnings results. Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases. Corcept reported revenues of $256.1 million, up 31.7% year on year. This print exceeded analysts’ expectations by 21.6%. Overall, it was an incredible quarter for the company with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations. Corcept achieved the biggest analyst estimate beat and highest full-year guidance raise of the whole group. Unsurprisingly, the stock is up 28.1% since reporting and currently trades at $119.05. Is now the time to buy Corcept? Access our full analysis of the earnings results here, it’s free. With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases. Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year, outperforming analysts’ expectations by 12.9%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. The market seems happy with the results as the stock is up 7.3% since reporting. It currently trades at $67.72. Is now the time to buy Bristol-Myers Squibb? Access our full analysis of the earnings results here, it’s free. Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide. Zoetis reported revenues of $2.47 billion, flat year on year, falling short of analysts’ expectations by 1.5%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations and a significant miss of analysts’ full-year EPS guidance estimates. Zoetis delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. Interestingly, the stock is up 3.6% since the results and currently trades at $77.08. Read our full analysis of Zoetis’s results here. Founded in 1876 by a Civil War veteran and pharmacist frustrated with the poor quality of medicines, Eli Lilly (NYSE:LLY) discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases. Eli Lilly reported revenues of $22.97 billion, up 47.7% year on year. This result surpassed analysts’ expectations by 11.4%. It was an exceptional quarter as it also put up a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. Eli Lilly pulled off the fastest revenue growth among its peers. The stock is up 14.6% since reporting and currently trades at $1,279. Read our full, actionable report on Eli Lilly here, it’s free. With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine. Supernus Pharmaceuticals reported revenues of $211.3 million, up 27.7% year on year. This print beat analysts’ expectations by 2.8%. Overall, it was a very strong quarter as it also produced full-year operating income guidance exceeding analysts’ expectations and full-year revenue guidance slightly topping analysts’ expectations. The stock is up 9.3% since reporting and currently trades at $48.80. Read our full, actionable report on Supernus Pharmaceuticals here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

This article first appeared on GuruFocus. Revenue: $256.1 million in Q2 2026, a 32% increase year-over-year. Korlym and Authorized Generic Revenue: $208.6 million. Lifyorli Revenue: $47.6 million in its first quarter of availability. Net Income: $43 million in Q2 2026, compared to $35 million in the prior-year period. Cash and Investments: $545 million as of June 30, 2026. 2026 Revenue Guidance: Increased to a range of $1.1 billion to $1.2 billion. Warning! GuruFocus has detected 8 Warning Signs with CORT. Is CORT fairly valued? Test your thesis with our free DCF calculator. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Record new prescriptions and first-time prescribers in Cushing's syndrome business, driving strong demand. Lifyorli launch in platinum-resistant ovarian cancer generated $47.6 million in first-quarter revenue with over 1,300 patients started. Positive CATALYST and MOMENTUM trial results are increasing physician awareness and screening for hypercortisolism. Relacorilant NDA resubmission accepted with PDUFA date of December 17, 2026, offering potential for accelerated growth. Promising Phase II DAZALS trial results for dazucorilant in ALS showed 84% reduction in risk of death at one year. Relacorilant's approval delayed due to a complete response letter from FDA, with resubmission only accepted in June 2026. Dazucorilant's gastrointestinal tolerability issues caused most discontinuations in the DAZALS trial. Lifyorli's duration of therapy is still early to assess, with limited long-term patient follow-up data. Potential competition from other therapies in Cushing's syndrome and oncology markets could impact growth. Dependence on successful Phase IIb MONARCH trial results for miricorilant in MASH, with data expected later this year. Q: Can you talk to the patient-level metrics on Lifyorli, including the number of patients on treatment currently, and whether the pace of patient adds is accelerating? Also, is the upward revision to guidance mostly related to the Lifyorli launch, and what are the dynamics surrounding Korlym?A: (Roberto Vieira, President - Oncology Division) We have initiated 1,300 patients on therapy since launch, with 1,000 unique prescribers. We are seeing a very broad range of patients, from early to late lines of therapy, and have maintained a strong pace of adding patients every week. We are on track to become market leaders and realize the $1 billion potential for platinum-resistant ovarian cancer. (Atabak Mokari, CFO) The new guidance range reflects strength across both our Endocrinology and Oncology businesses. Q: On Lifyorli, how much of the $48 million in revenue reflects dispensed demand versus initial channel build? Also, how many unique prescribers do you have beyond the 200 cited in April, and what is the duration of therapy? On Korlym, how much of the 27% sequential growth is from clearing the pharmacy transition backlog versus new capacity?A: (Atabak Mokari, CFO) There is very little inventory contribution in the quarter results. On the Cushing's syndrome side, almost 100% of business goes through specialty pharmacy, which is direct to patient. On the oncology side, about 30% goes through specialty pharmacy, and the rest through specialty distributors who hold minimal inventory (about one week of demand). (Sean Maduck, President - Corcept Endocrinology) The $44 million growth from Q2 over Q1 was not driven by a catch-up from the pharmacy transition, which is behind us. It was driven by continued servicing of our existing patient base and a record number of new enrollments. Q: What is the status of the relacorilant NDA resubmission for Cushing's syndrome, and what is the expected timeline for approval?A: (Joseph Belanoff, CEO) We resubmitted our NDA on June 17 after completing additional analyses requested by the FDA. The FDA accepted the resubmission and assigned a PDUFA date of December 17, 2026. Relacorilant's availability will accelerate growth in our Cushing's syndrome business. Q: What are the key results from the CATALYST and MOMENTUM trials, and how are they driving physician awareness and business growth?A: (Sean Maduck, President - Corcept Endocrinology) CATALYST showed 24% of patients with difficult-to-treat diabetes had hypercortisolism, and treatment with Korlym led to substantial reductions in HbA1c, weight, and waist circumference. MOMENTUM found 27% of patients with resistant hypertension had hypercortisolism. These paradigm-shifting findings are driving increased screening and treatment, leading to record new prescriptions and first-time prescribers. We expect this to propel our Cushing's syndrome business to at least $2 billion in annual revenue by the end of this decade. Q: What is the potential for GR antagonism in oncology beyond platinum-resistant ovarian cancer, and what are the upcoming data readouts?A: (Joseph Belanoff, CEO) GR antagonism has the potential to treat any solid tumor expressing the GR. Our BELLA trial (platinum-resistant and sensitive ovarian cancer, endometrial cancer), STELLA trial (cervical cancer), and TRIDENT trial (pancreatic cancer) will all produce results by the end of next year. Successful results could increase the number of patients relacorilant may help by fivefold. We also initiated the SYNERGY Phase Ib study of nenocorilant with nivolumab across solid tumors, with results expected by the end of next year. Q: What are the latest developments in the ALS program with dazucorilant, and what are the next steps?A: (Joseph Belanoff, CEO) In the DAZALS Phase II trial, patients receiving 300 mg of dazucorilant showed an 84% reduction in risk of death at one year (p=0.0009) and an 87% reduction at two years (p<0.0001). We are conducting a dose titration study to improve gastrointestinal tolerability, which caused most discontinuations. Findings will inform the design of a pivotal trial we plan to start early next year. Q: What is the status of the MASH program with miricorilant, and when can we expect data?A: (Joseph Belanoff, CEO) Our 175-patient Phase IIb MONARCH study has completed enrollment and will produce data later this year. In our Phase Ib study, miricorilant rapidly reduced liver fat and improved markers of liver health, including fibrosis, and was well tolerated. Positive results would support advancement to Phase III. Q: What are the key financial results for the second quarter of 2026?A: (Atabak Mokari, CFO) Revenue was $256.1 million, a 32% increase year-over-year. Korlym and authorized generic revenue was $208.6 million. Lifyorli product revenue was $47.6 million in its first quarter of availability. Net income was $43 million. We increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Cash and investments at June 30 were $545 million. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Corcept Therapeutics CORT reported second-quarter 2026 earnings of 36 cents per share, beating the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company had reported earnings of 29 cents. Second-quarter revenues rose nearly 32% year over year to $256.1 million and surpassed the Zacks Consensus Estimate of $216 million. Growth was driven by higher Korlym sales and the first-quarter contribution from newly launched ovarian cancer drug Lifyorli (relacorilant). Year to date, shares of Corcept have surged 167.1% against the industry’s 2.4% decline. Image Source: Zacks Investment Research Corcept’s top line consisted of product sales from Cushing’s syndrome drug Korlym and newly launched ovarian cancer drug Lifyorli. In the second quarter of 2026, product revenues from Korlym were $208.6 million, up 7.3% year over year. However, the metric missed our model estimate of $212.2 million. In March 2026, the FDA approved Lifyorli, Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Lifyorli generated $47.6 million in its first quarter of commercial availability. The reported figure surpassed our model estimate of $2 million. More than 1,300 patients started treatment by the earnings update, while more than 1,000 physicians prescribed the drug. Management attributed uptake to Lifyorli’s efficacy and safety profile, oral administration and lack of a biomarker requirement. The regimen was listed as a preferred option in the NCCN Guidelines shortly after approval. Second-quarter operating expenses increased 28.1% year over year to $214.8 million. The rise reflected spending related to the Lifyorli launch and continued investment in the company’s Cushing’s syndrome business. Selling, general and administrative expenses surged 51.1% to $156.9 million. Research and development expenses declined 10.9% to $53.9 million. Corcept ended the quarter with cash and investments of $544.6 million, up from $515.4 million as of March 31, 2026. Corcept raised its 2026 revenue guidance to $1.1-$1.2 billion from the previous $950 million to $1.05 billion. Management said that the revised outlook reflects strength across the endocrinology and oncology businesses. The Zacks Consensus Estimate for revenues is pegged at $986.45 million. Corcept continued to make meaningful progress across its late-stage pipeline. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026. The NDA filing is supported by positive data from the GRACE study, confirmatory evidence from the phase III GRADIENT study, long-term extension studies and a phase II study in hypercortisolism. Corcept is evaluating relacorilant plus nab-paclitaxel and bevacizumab in the phase II BELLA study in patients with platinum-resistant ovarian cancer to understand whether combining relacorilant with two medicines offers patients an additional treatment option or not. Top-line data are expected by the end of 2026. Additional studies investigating relacorilant across platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers remain on track to report results by the end of 2027. Patient enrollment is ongoing in the mid-stage prostate cancer study. Corcept has submitted a marketing authorization application to the European Medicines Agency, seeking approval for relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer. A final decision in Europe is expected by the end of 2026. Beyond relacorilant, Corcept continues to advance its broader pipeline. Corcept is developing its other pipeline candidates, dazucorilant and miricorilant, in separate studies for treating amyotrophic lateral sclerosis (ALS) and biopsy-confirmed or presumed metabolic dysfunction-associated steatohepatitis, respectively. The phase IIb MONARCH study of miricorilant in patients with metabolic dysfunction-associated steatohepatitis has completed enrollment. Results are expected by the end of this year. Corcept is also conducting a dose-titration study of dazucorilant in ALS to improve gastrointestinal tolerability. The findings are expected to guide a planned phase III study after phase II DAZALS analyses showed substantial reductions in mortality risk at the 300-milligram dose. Corcept Therapeutics Incorporated price-consensus-eps-surprise-chart | Corcept Therapeutics Incorporated Quote Corcept currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy), and Neurocrine Biosciences NBIX, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.2% year to date. Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 151.7% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%. Over the past 90 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $8 to $9.09. Over the same period, EPS estimates for 2027 have increased from $9.48 to $10.81. NBIX shares have gained 27.5% year to date. Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Increase in 2026 revenue guidance to $1.1 – $1.2 billion Net income of $43.0 million, compared to $35.1 million in second quarter 2025 Cash and investments of $544.6 million at June 30, 2026 REDWOOD CITY, Calif., July 29, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results "Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter. In our oncology business, over 1,300 patients have now started treatment with Lifyorli following FDA approval in March 2026. Demand for Lifyorli has accelerated each month with physicians responding favorably to Lifyorli’s efficacy and safety profile, oral administration and lack of biomarker requirement. Our Cushing’s syndrome business, once again, had a record number of new prescriptions written for our medications as physicians increasingly recognize hypercortisolism’s true prevalence and the necessity of appropriate treatment. We expect this trend to continue as the findings from our CATALYST and MOMENTUM studies are fully incorporated into clinical practice. We anticipate continued strength across our businesses and have increased our 2026 revenue guidance to $1.1 – $1.2 billion," said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. Corcept’s second quarter 2026 revenue was $256.1 million, compared to $194.4 million in the second quarter of 2025. Korlym and authorized generic product revenue was $208.6 million, compared to $194.4 million in the prior year period. Lifyorli product revenue was $47.6 million in its first quarter of availability. Second quarter 2026 operating expenses were $214.8 million, compared to $167.8 million in the same period in 2025, due to increased spending to launch Lifyorli and investments in our Cushing’s syndrome business. Net income per common share (diluted) was $0.36 in the second quarter of 2026, compared to $0.29 in the prior year period. Cash and investments were $544.6 million at June 30, 2026, compared to $515.4 million at March 31, 2026. Clinical Development "The FDA’s approval of Lifyorli (relacorilant) in platinum-resistant ovarian cancer is the first step in advancing glucocorticoid receptor antagonism as a treatment for many types of cancer. Our oncology development program aims to establish the broad utility of our medicines to help many more patients. We anticipate that the European Medicines Agency will approve our Marketing Authorization Application of relacorilant in platinum-resistant ovarian cancer later this year. We expect results from our trial of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer by the end of this year. Our studies of relacorilant to treat platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers are expected to produce results by the end of next year. Our study of nenocorilant with the PD-1 checkpoint inhibitor nivolumab to treat a variety of solid tumors will also produce results by the end of next year," said Dr. Belanoff. "We resubmitted our New Drug Application (NDA) for relacorilant in Cushing’s syndrome in June. Relacorilant has the potential to help many patients and it’s important it is available as quickly as possible. We expect a decision on our NDA by December 17, 2026. In addition, results from MONARCH, our Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected by the end of this year. We also plan to start a Phase 3 trial of dazucorilant in patients with ALS, with the goal of replicating the significant survival benefit observed in our Phase 2 DAZALS study," added Dr. Belanoff. Hypercortisolism (Cushing’s Syndrome) Relacorilant for patients with Cushing’s syndrome – New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 GRACE – Pivotal Phase 3 trial of relacorilant in 152 patients with Cushing’s syndrome – Results published in The Lancet Diabetes & Endocrinology (Pivonello et al, February 2026) CATALYST and MOMENTUM – New data presented at American Diabetes Association’s (ADA) 86th Scientific Sessions in June "Our studies have shown that patients with hypercortisolism who receive relacorilant experience clinically and statistically significant improvements in the multiple signs and symptoms of the disease. Importantly, relacorilant delivers these improvements without the off-target effects and serious adverse events associated with currently available treatments," said Bill Guyer, PharmD, Corcept’s Chief Development Officer. "Relacorilant has the potential to become the new standard of care." "The need for better treatment for patients with hypercortisolism is urgent. Our CATALYST and MOMENTUM studies demonstrate that hypercortisolism is an underlying driver of disease for many patients with diabetes and hypertension whose health is at risk because their disease isn’t adequately managed with standard-of-care treatments. These findings will lead to increased screening and improved treatment for patients with hypercortisolism," added Dr. Guyer. Oncology Relacorilant in Combination with Chemotherapy FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer in March 2026 Lifyorli plus nab-paclitaxel added to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred regimen in April 2026 Marketing Authorization Application (MAA) – European Medicines Agency reviewing MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer – Approval expected by the end of this year ROSELLA – Pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in 381 patients with platinum-resistant ovarian cancer – Both dual primary endpoints (progression-free and overall survival) met – Results published in The Lancet (Lorusso et al, April 2026) BELLA Part A – Enrollment completed in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer – Results expected by the end of this year BELLA Part B – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 90 patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARP inhibitor – Results expected by the end of next year BELLA Part C – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel in 90 patients with endometrial cancer (who have received one or two prior lines of therapy) – Results expected by the end of next year STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO – Results expected by the end of next year TRIDENT – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and gemcitabine as first-line therapy in 60 patients with pancreatic cancer – Results expected by the end of next year Relacorilant in Combination with Androgen Deprivation Therapy Prostate cancer – Enrollment continues in randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in 90 patients with early-stage prostate cancer, conducted in collaboration with the University of Chicago Nenocorilant in Combination with Immunotherapy SYNERGY – Enrollment continues in Phase 1b dose-finding trial of nenocorilant plus nivolumab in 30 patients with a variety of solid tumors – Results expected by the end of next year "There is tremendous potential for glucocorticoid receptor antagonism to help treat many types of solid tumors. Our Phase 3 ROSELLA trial demonstrated that adding Lifyorli to nab-paclitaxel chemotherapy reduced the risk of death in patients with platinum-resistant ovarian cancer by 35 percent, without the need for biomarker selection. Our ongoing oncology studies, many of which will produce results by the end of next year, build on these findings by evaluating the role of our medications across a broad range of tumor types and treatment combinations. We will continue to advance and expand our research to realize the substantial opportunity before us," added Dr. Guyer. Metabolic Dysfunction-Associated Steatohepatitis (MASH) MONARCH – Enrollment completed in randomized, double-blind, placebo-controlled, Phase 2b trial of miricorilant in 175 patients with biopsy-confirmed or presumed MASH – Results expected by the end of this year "Data from our Phase 1b study demonstrated that miricorilant rapidly reduced liver fat while improving fibrosis, liver enzymes and other markers of liver health, including key metabolic and lipid measures. We look forward to building on these promising findings in our Phase 2b MONARCH study, with results expected by the end of this year," said Dr. Guyer. Amyotrophic Lateral Sclerosis (ALS) DAZALS – Exploratory analyses showed that patients who received dazucorilant 300 mg exhibited an 84 percent reduction in risk of death during the study’s first year compared to patients who received placebo (hazard ratio: 0.16, p-value: 0.0009) – This benefit persisted into the study’s second year with an 87 percent reduction in risk of death (hazard ratio: 0.13, p-value: Phase 3 trial – Planned to begin early next year "Patients with ALS often have elevated cortisol levels. Data from our Phase 2 DAZALS study showed that patients treated with dazucorilant exhibited a profound reduction in early mortality, during a period when many patients with ALS still retain significant function and maintain good quality of life," said Dr. Guyer. "Our ongoing dose-titration study’s goal is to improve gastrointestinal tolerability and inform next steps for this program." Conference Call We will hold a conference call on July 29, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. A listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with Cushing’s syndrome, solid tumors, ALS and liver disease. In 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome, and in 2026, the company introduced Lifyorli, approved in combination with nab-paclitaxel, the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements. In this press release, forward-looking statements include those concerning: the anticipated continued strength across our businesses; our 2026 revenue guidance; our expectation that the trend related to the number of new prescriptions written for our medications will continue as physicians increasingly recognize the prevalence of hypercortisolism and the necessity of treatment; the potential for glucocorticoid receptor antagonism to be a treatment for many types of cancer and solid tumors; our anticipation that the European Medicines Agency will approve our MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer this year; resubmission of our NDA for relacorilant for the treatment of patients with Cushing’s syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026; the potential for relacorilant to help many patients and the importance of relacorilant becoming available as quickly as possible; statements related to ongoing oncology clinical trials of relacorilant or nenocorilant in combination with nab-paclitaxel, other chemotherapy, androgen deprivation therapy or immunotherapy, including statements regarding the potential to produce important data, expected patient enrollment, and the expected timing of results from these trials; our plan to begin a Phase 3 trial in the treatment of patients with ALS early next year with the goal of replicating the significant survival benefit observed in our Phase 2 DAZALS study; relacorilant’s potential to become the new standard of care for treatment of patients with hypercortisolism; the findings of our CATALYST and MOMENTUM studies and the possibility that these findings will lead to increased screening and improved treatment for patients with hypercortisolism; the expectation that we will have results from our Phase 2b MONARCH study of miricorilant in patients with MASH by the end of 2026 and our ability to build on the findings from this study; and our intent to use our ongoing dose-titration study of dazucorilant to improve gastrointestinal tolerability of treatment and inform next steps for our ALS program. A further description of risks and uncertainties can be found in our SEC filings, which are available at our website and the SEC’s website. These risks and uncertainties include, but are not limited to, those related to our ability to: operate our business; study and develop Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules’ clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260729465503/en/ Contacts Investor inquiries:[email protected] Media inquiries:[email protected] www.corcept.com

Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better. Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome business and $47.6 million from newly launched ovarian cancer drug LIFYORLI. Corcept raised its 2026 revenue guidance to $1.1 billion–$1.2 billion. LIFYORLI’s launch is gaining traction, with more than 1,300 patients treated, over 1,000 prescribing physicians and coverage policies for more than 70% of relevant insured lives. Corcept expects the therapy’s U.S. revenue in platinum-resistant ovarian cancer to eventually exceed $1 billion annually. The FDA accepted Corcept’s resubmitted relacorilant application for Cushing’s syndrome and set a December 17, 2026, action date, while pipeline studies continue in cancer, MASH and ALS. 3 Biopharmaceutical Stocks Bucking the Sell-Off Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability. Net income rose to $43 million from $35 million a year earlier. Chief Financial Officer Atabak Mokari said operating expenses were flat compared with the first quarter, while cash and investments totaled $545 million as of June 30. → This Tiny AI Supplier Could Be More Important Than the Chipmakers The company raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Mokari said the updated outlook reflects strength in both Corcept’s endocrinology and oncology businesses. Corcept’s LIFYORLI, approved by the FDA on March 25 for platinum-resistant ovarian cancer, generated $47.6 million in revenue after the company began selling the treatment April 1. Roberto Vieira, president of Corcept’s oncology division, described the launch as one of the strongest for an oncology medication. → Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Vieira said more than 1,300 patients have started treatment with LIFYORLI and more than 1,000 physicians have prescribed it to at least one patient. He said demand has come from academic and non-teaching hospitals as well as community oncology clinics. According to the company, more than 70% of combined Medicare, Medicaid and commercial insurance lives had formal coverage policies for LIFYORLI in place as of the call. The National Comprehensive Cancer Network listed the therapy as a preferred regimen 15 days after its approval, Corcept said. → Innovative ETF Strategies That Are Paying Off This Summer Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI’s U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff. He said the combination significantly delayed disease progression and extended overall survival compared with nab-paclitaxel alone. The company reported a 35% reduction in the risk of death, corresponding to a hazard ratio of 0.65 and a P value of 0.0004. Korlym and authorized generic product revenue totaled $208.6 million during the quarter. Sean Maduck, president of Corcept’s endocrinology division, said the company recorded a record number of new prescriptions, first-time prescribers and patients receiving its Cushing’s syndrome medications. Maduck attributed growth to increased physician awareness of hypercortisolism, which can contribute to difficult-to-treat diabetes and resistant hypertension. He cited the company’s CATALYST and MOMENTUM studies, which found hypercortisolism in portions of patients screened for those conditions. In response to analyst questions, Maduck said the specialty-pharmacy transition is behind the company and that second-quarter growth was not primarily driven by clearing a backlog. Rather, he said performance reflected continued service of existing patients and a record number of new enrollments. Belanoff said the FDA accepted Corcept’s resubmitted new drug application for relacorilant in Cushing’s syndrome and assigned a Prescription Drug User Fee Act date of Dec. 17, 2026. Corcept resubmitted the application June 17 after the FDA requested additional analyses of the data from the company’s original application during an April meeting. The application is supported by the Phase III GRACE trial and evidence from the Phase III GRADIENT trial, a long-term extension study and earlier development work, Belanoff said. He said the company believes relacorilant demonstrated durable improvement in signs and symptoms of Cushing’s syndrome without certain serious adverse events associated with currently approved medications. Corcept is evaluating relacorilant with chemotherapy in several solid tumors. Belanoff said one arm of the BELLA study in platinum-resistant ovarian cancer is expected to produce results this year, while additional BELLA arms in platinum-sensitive ovarian cancer and endometrial cancer, along with the STELLA cervical cancer trial and TRIDENT first-line pancreatic cancer trial, are expected to report results by the end of 2027. The company also initiated the Phase Ib SYNERGY study of nenicorilant with nivolumab across a range of solid tumors, with results expected by the end of next year. Outside oncology, Corcept said its 175-patient Phase IIb MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis, or MASH, has completed enrollment and is expected to produce data later this year. Positive results could support advancement to Phase III, Belanoff said. For ALS, the company is conducting a dose-titration study of dazucorilant to improve gastrointestinal tolerability ahead of a planned pivotal trial expected to begin early next year. Belanoff cited Phase II DAZALS results showing reduced risk of death among patients receiving the 300-milligram dose, while noting that non-serious gastrointestinal distress accounted for most treatment discontinuations. Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Corcept Therapeutics Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1,000.00%. A quarter ago, it was expected that this drug developer would post a loss of $0.3 per share when it actually produced a loss of $0.3, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $256.15 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 18.38%. This compares to year-ago revenues of $194.43 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Corcept shares have added about 170.7% since the beginning of the year versus the S&P 500's gain of 8.5%. While Corcept has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Corcept was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.31 on $272.69 million in revenues for the coming quarter and $0.53 on $986.45 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Madrigal (MDGL), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 30. This biopharmaceutical company is expected to post quarterly loss of $2.55 per share in its upcoming report, which represents a year-over-year change of -34.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Madrigal's revenues are expected to be $349.34 million, up 64.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Madrigal Pharmaceuticals, Inc. (MDGL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Recently, Corcept Therapeutics received an upgraded Zacks Rank of #2 (Buy) after analysts sharply raised their full-year earnings estimates, reflecting a much stronger profit outlook than previously expected. This improved earnings view has come alongside performance that has far outstripped the broader Medical sector and the Medical – Drugs industry, underlining how quickly sentiment can shift when projections change. We’ll now examine how this strengthened earnings outlook and analyst sentiment may influence Corcept Therapeutics’ existing investment narrative. The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. To own Corcept Therapeutics, you need to be comfortable with a company in transition, moving from reliance on Korlym toward a broader relacorilant and oncology franchise. The sharply improved earnings outlook and Zacks Rank upgrade spotlight stronger near term profit expectations, but they do not remove the central risks around Korlym pricing pressure and ongoing patent and legal overhangs, which remain key swing factors for the story in the short term. The most relevant recent development here is Corcept’s March 2026 FDA approval of Lifyorli (relacorilant) with nab paclitaxel for platinum resistant ovarian cancer, supported by ROSELLA data. This new indication sits at the heart of the bullish earnings revisions, because it begins to diversify revenue away from Korlym and ties directly into the thesis that relacorilant can open multiple treatment franchises if adoption and reimbursement trends prove supportive. Yet, while the stock’s upgraded earnings outlook is encouraging, investors should also be aware of how unresolved Korlym patent appeals could still reshape the story if... Read the full narrative on Corcept Therapeutics (it's free!) Corcept Therapeutics' narrative projects $1.9 billion revenue and $910.1 million earnings by 2029. This requires 34.6% yearly revenue growth and about an $863 million earnings increase from $46.7 million today. Uncover how Corcept Therapeutics' forecasts yield a $88.00 fair value, a 8% downside to its current price. Some of the lowest ranked analysts were already cautious, assuming revenue of about US$1.5 billion and earnings of roughly US$478.5 million by 2029, so this upgraded earnings outlook may eventually prompt them to revisit their more pessimistic view and gives you a chance to compare how different investors weigh relacorilant’s potential against Korlym’s patent and pricing risks. Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth as much as 77% more than the current price! Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Corcept Therapeutics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance. Our top stock finds are flying under the radar-for now. Get in early: Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CORT. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]